$830,000.00 in Sales Expected for Proteostasis Therapeutics Inc (PTI) This Quarter
Equities analysts expect Proteostasis Therapeutics Inc (NASDAQ:PTI) to report sales of $830,000.00 for the current quarter, according to Zacks. Two analysts have made estimates for Proteostasis Therapeutics’ earnings, with the highest sales estimate coming in at $850,000.00 and the lowest estimate coming in at $800,000.00. Proteostasis Therapeutics reported sales of $1.55 million during the same quarter last year, which would suggest a negative year-over-year growth rate of 46.5%. The firm is expected to issue its next earnings report on Tuesday, November 13th.
According to Zacks, analysts expect that Proteostasis Therapeutics will report full year sales of $3.67 million for the current fiscal year, with estimates ranging from $3.49 million to $3.84 million. For the next year, analysts expect that the firm will post sales of $3.52 million, with estimates ranging from $3.50 million to $3.53 million. Zacks’ sales calculations are a mean average based on a survey of analysts that that provide coverage for Proteostasis Therapeutics.
Proteostasis Therapeutics (NASDAQ:PTI) last issued its earnings results on Wednesday, August 8th. The company reported ($0.43) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.04). Proteostasis Therapeutics had a negative net margin of 1,309.13% and a negative return on equity of 104.16%. The business had revenue of $0.84 million for the quarter, compared to the consensus estimate of $1.16 million.
PTI stock traded down $0.17 during midday trading on Monday, reaching $7.02. 659,377 shares of the company’s stock traded hands, compared to its average volume of 7,768,375. Proteostasis Therapeutics has a 52 week low of $1.41 and a 52 week high of $10.38. The stock has a market capitalization of $253.58 million, a price-to-earnings ratio of -3.00 and a beta of -3.25.
In related news, Director Franklin M. Berger bought 40,000 shares of the business’s stock in a transaction that occurred on Friday, October 26th. The stock was bought at an average cost of $6.75 per share, for a total transaction of $270,000.00. Following the completion of the transaction, the director now owns 266,162 shares of the company’s stock, valued at $1,796,593.50. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 19.80% of the stock is currently owned by insiders.
A number of large investors have recently made changes to their positions in PTI. BlackRock Inc. lifted its stake in Proteostasis Therapeutics by 3,693.4% in the second quarter. BlackRock Inc. now owns 1,807,717 shares of the company’s stock worth $5,043,000 after purchasing an additional 1,760,063 shares during the last quarter. Northern Trust Corp lifted its stake in Proteostasis Therapeutics by 526.1% in the second quarter. Northern Trust Corp now owns 269,451 shares of the company’s stock worth $752,000 after purchasing an additional 226,417 shares during the last quarter. Bailard Inc. lifted its stake in Proteostasis Therapeutics by 12.0% in the second quarter. Bailard Inc. now owns 582,400 shares of the company’s stock worth $1,625,000 after purchasing an additional 62,300 shares during the last quarter. Acadian Asset Management LLC bought a new stake in Proteostasis Therapeutics in the second quarter worth $141,000. Finally, Bank of New York Mellon Corp lifted its stake in Proteostasis Therapeutics by 252.8% in the second quarter. Bank of New York Mellon Corp now owns 62,319 shares of the company’s stock worth $174,000 after purchasing an additional 44,653 shares during the last quarter. Institutional investors own 64.57% of the company’s stock.
Proteostasis Therapeutics Company Profile
Proteostasis Therapeutics, Inc, a clinical stage biopharmaceutical company, discovers and develops novel therapeutics to treat cystic fibrosis and other diseases caused by an imbalance in the proteostasis network. Its lead product candidate is PTI-428, an orally bioavailable cystic fibrosis transmembrane conductance regulator modulator belonging to the amplifier class, which is in Phase II study.
Recommended Story: Technical Analysis
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Proteostasis Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Proteostasis Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.